| Ytd | -26.81% | |
| 1y | -60.50% |
| Open | 3.82 | Prev Close | 3.78 | Low | 3.70 | High | 3.90 | Mkt Cap | 4.21M |
| Vol | 9.41K | Avg Vol | 159.16K | EPS | -3.10 | P/E | -1.20 | Forward P/E | -1.26 |
| Beta | 0.71 | Short Ratio | 0.98 | Inst. Own | 2.46% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-15 | 50-d Avg | 5.48 | 200-d Avg | 5.90 | 1yr Est | 10.00 |
SILO News
Gainers AbCellera Biologics (NASDAQ:ABCL) shares increased by 8.2% to $7.5 during Friday's afte
Collaboration supports development of a next-generation AWS-native platform designed to accelerate c
Silo Pharma, Inc. (NASDAQ: SILO - Get Free Report) was the recipient of a large increase in short in
Silo continues to add technology assets as it expands its AI business and further develops its lead
Silo Pharma Incs (NASDAQ:SILO) announced on Tuesday that its wholly owned subsidiary, QwikAgents, ha
Silo Pharma's QwikAgents joins AMD's AI Developer Program, gaining cloud credits and tools t
Silo Pharma (NASDAQ:SILO) ("Silo" or "the Company"), a diversified developmental-sta
SARASOTA, FLA. , July 14, 2026 (GLOBE NEWSWIRE) -- Silo Pharma (Nasdaq: SILO) ("Silo" or "the Compan
Apple partners with Broadcom on a multiyear agreement exceeding $30 billion to develop custom silico
Gainers EUDA Health Holdings (NASDAQ:EUDA) shares rose 22.3% to $15.2 during Friday's regular s
$4 million upfront with up to approximately $7.7 million of potential additional gross proceeds upon
NVIDIA Corp. (NASDAQ:NVDA) expanded its presence in life sciences AI through separate initiatives wi
Nvidia expands its life sciences AI ecosystem through a Certara partnership and QwikAgents' entr
NVIDIA developer program resources expected to support autonomous AI agent innovation and marketing
Study designed to evaluate performance and formulation stability of proprietary nose-to-brain delive
Positive data supports the continued advancement of FDA Investigational New Drug (IND)- enabling dev
SARASOTA, FLA., June 18, 2026 (GLOBE NEWSWIRE) -- Silo Pharma (Nasdaq: SILO) (“Silo” or “the Company
New initiative from Silo Pharma designed to align with federal actions to accelerate mental health i
Federal initiatives focused on PTSD and related conditions appears to validate need for new and nove
Silo Pharma, Inc. (NASDAQ: SILO - Get Free Report) was the target of a significant growth in short i
Launch of Dedicated AI Subsidiary Positions Company for New Revenue Streams While Advancing PTSD Pro
SILO stock rose 51.8% in pre-market trading after its PTSD treatment pipeline received a patent from
During the session on Thursday, 461 stocks hit new 52-week lows.